Stock LPTX LEAP THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Leap Therapeutics, Inc.

Equities

LPTX

US52187K2006

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-08 pm EDT 		5-day change 1st Jan Change
1.93 USD -3.50% Intraday chart for Leap Therapeutics, Inc. +3.21% -53.44%
Jul. 01 Leap Therapeutics, Inc.(NasdaqCM:LPTX) added to Russell 3000E Index CI
Jul. 01 Leap Therapeutics, Inc.(NasdaqCM:LPTX) added to Russell Microcap Index CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Leap Therapeutics Announces $40 Million Private Placement
PR
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
PR
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients
PR
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium
AQ
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference
PR
Leap Therapeutics Reports Third Quarter 2023 Financial Results
PR
Leap Therapeutics to Participate at Upcoming Investor Conferences
PR
Leap Therapeutics Reports Second Quarter 2023 Financial Results
AQ
Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients
PR
Leap Therapeutics Announces Reverse Stock Split
PR
Leap Therapeutics Reports First Quarter 2023 Financial Results
AQ
Leap Therapeutics : Reports First Quarter 2023 Financial Results - Form 8-K
PU
LEAP THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Leap Therapeutics : Announces Completion of Enrollment in Part A of the DeFianCe Study of - Form 8-K
PU
LEAP THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
PR
LEAP THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
AQ
LEAP THERAPEUTICS, INC. Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits (form 8-K/A)
AQ
LEAP THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LPTX Stock
  4. News Leap Therapeutics, Inc.
  5. Press Releases